Life Sciences

  • September 29, 2026

    USPTO Details Best Practices For Subject Matter Declarations

    Patent applicants submitting declarations explaining why their patents are eligible under Section 101 of the Patent Act should hand in those statements separately from other evidence and also send them in sooner rather than later, U.S. Patent and Trademark Office Director John Squires recommended on Tuesday.

  • September 29, 2026

    Oura Cites Market 'Uncertainty' In Delaying Estimated $2B IPO

    Fitness-tracking ring maker Oura on Tuesday revealed that it is delaying its planned initial public offering, citing "uncertainty in the IPO market," just a week after the company told U.S. regulators that it hoped to raise $2.1 billion in the public debut.

  • September 28, 2026

    Bayer's COVID Vax IP Suits Against Moderna, Pfizer Survive

    Bayer CropScience was cleared to pursue its patent infringement suits against COVID-19 vaccine makers Pfizer, BioNTech and Moderna, after a judge sitting in Delaware upheld its cases on Monday.

  • September 28, 2026

    Fla. Judge Axes Pot Co.'s THC Patent Suit Against Trulieve

    A Florida federal judge on Monday granted cannabis company Trulieve Inc.'s request to toss a rival patent company's complaint alleging Trulieve infringed several of the rival's patents.

  • September 28, 2026

    3 Firms Lead $663.7M Lifecore Biomedical Take-Private Deal

    Lifecore Biomedical Inc. on Monday unveiled plans to become a private company after it is bought by private equity shop Webster Equity Partners in a deal valued at up to $663.7 million that was built by three law firms.

  • September 28, 2026

    Wellness Biz Sued Over 'Immunity,' 'Doctor Crafted' Claims

    A proposed class says Vive Organic Inc. deceptively labeled its wellness shots as "immunity boosting" and "doctor crafted" despite lacking evidence of clinical or medical trials showing that they can protect against infection or illness.

  • September 28, 2026

    Insurer Seeks Exit From Pharma Co.'s $50M Creditor Dispute

    An insurer for a San Francisco pharmaceutical company told a California federal court it owes no duty to defend the company in a suit from a creditor and shareholder alleging directors and officers mismanaged the company to protect their equity, saying a creditors exclusion bars coverage.

  • September 28, 2026

    Lantheus Investor Asks Court To Halt 'Unfair' $8B Curium Deal

    A Lantheus Holdings Inc. investor wants a Massachusetts state judge to block its $8 billion take-private deal with fellow radiopharmaceutical company Curium in its current form, calling the deal "fundamentally unfair" to shareholders.

  • September 28, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court this past week heard arguments over whether to dismiss a derivative suit accusing UiPath Inc. insiders of misleading investors and trading on inside information, while a Match Group Inc. stockholder sued for records concerning reports of sexual assault and other violence involving users of the company's dating apps.

  • September 28, 2026

    Trump Asks Justices To Restore Fed. Prison Trans Care Ban

    The Trump administration urged the U.S. Supreme Court on Monday to halt a district court order barring the Bureau of Prisons from enforcing a ban on gender dysphoria care for transgender people incarcerated in BOP facilities, arguing the lower court stepped beyond its proper role. 

  • September 28, 2026

    Seed Patent Dispute Settles 3 Days Into Trial

    Corteva Agriscience and Inari Agriculture Inc. have settled a seed intellectual property dispute three days into a Delaware federal trial over whether the latter infringed three patents and misappropriated seed samples.

  • September 25, 2026

    SEC Says Mich. Atty Tipped Family About Pharma Co. Merger

    The U.S. Securities and Exchange Commission on Friday accused a Michigan tax lawyer of insider trading, alleging he told his brother and cousin about a planned but not-yet-announced merger between Y-mAbs Therapeutics Inc. and SERB Pharmaceuticals.

  • September 25, 2026

    SEC Says Md. Woman Illegally Traded On FDA Approval Info

    The SEC accused a Maryland resident of trading on nonpublic information she received from an insider ahead of the FDA's 2023 denial of a new drug application for a depression treatment submitted by Sage Therapeutics Inc. that caused the company's shares to lose over half of their value.

  • September 25, 2026

    Teva, Apotex Don't Infringe Sleep Drug Patents, Judge Finds

    Generic drugmakers Teva Pharmaceuticals and Apotex Inc. have secured an order from a Delaware federal court that they do not infringe patents asserted by Vanda Pharmaceuticals that cover the sleep drug Hetlioz.

  • September 25, 2026

    PTAB Invalidates Challenged Claims In Breast Pump Patent

    The Patent Trial and Appeal Board on Friday ruled that all claims Shenzhen Root Technology Co. Ltd. challenged in a Willow Blossom wearable breast pump patent are invalid on numerous grounds.

  • September 25, 2026

    AbbVie Says Botox Exempt From Medicare Price Negotiations

    AbbVie largely backed away from its constitutional challenges to the Inflation Reduction Act's Drug Price Negotiation Program in D.C. federal court Friday, but still insisted that its suite of Botox drugs can't be forced into negotiations with Medicare over price because they feature enough human plasma to fit into a congressional exemption.

  • September 25, 2026

    Alkermes Must Face Bulk Of Addiction Treatment Drug Suit

    A Massachusetts federal judge largely refused Thursday to let Alkermes duck a proposed class action alleging it tricked the U.S. Patent and Trademark Office into granting a patent for the addiction treatment therapy Vivitrol, crediting allegations a missing study was intentionally omitted from the patent application to win approval.

  • September 25, 2026

    Squires Says Biocon Challenge To Eylea Patent Filed Too Late

    U.S. Patent and Trademark Office Director John Squires has explained why he rejected Biocon Biologics' challenge to a Regeneron Pharmaceuticals Inc. patent covering the eye disorder drug Eylea — because Biocon waited too long to bring the challenge.

  • September 25, 2026

    COVID Testing Co.'s Ex-COO Pleads Guilty In $500M Fraud

    The former chief operating officer of a COVID-19 testing company pled guilty in Michigan federal court to a healthcare fraud conspiracy allegedly involving more than $500 million in fraudulent insurance claims for services that were not performed as billed.

  • September 25, 2026

    Del. Chancery Says Curonix Owns Stimwave Shares

    The medical device company Curonix LLC has won its lawsuit against the founder of Stimwave Technologies Inc., with Delaware's Court of Chancery finding that the plaintiff is the rightful holder of 75,000 shares of the company it purchased in bankruptcy.

  • September 25, 2026

    Cooley, Latham Steer RNA Drugmaker's Upsized $446M IPO

    San Diego-based biotechnology company ADARx Pharmaceuticals began trading publicly on Friday after raising $446 million in its initial public offering steered by Cooley LLP and Latham & Watkins LLP, adding to the growing list of biotech IPOs recently.

  • September 25, 2026

    Novo Bets $1.3B On Nanexa Drug Tech Amid Obesity Push

    Novo Nordisk has agreed to pay up to about €1.165 billion ($1.3 billion) under an exclusive license and collaboration agreement for Swedish drug-delivery company Nanexa's PharmaShell technology.

  • September 25, 2026

    Taxation With Representation: Kirkland, Latham, McDermott

    In this week's Taxation With Representation, Royal Caribbean invests billions in a joint venture with Sandals, Telix Pharmaceuticals buys ITM Isotope Technologies Munich, and Priority Technology makes a go-private deal with an investor group helmed by the company's chair and CEO.

  • September 24, 2026

    Jurisdictional Skepticism Puts Eli Lilly Appeal On Thin Ice

    Eli Lilly & Co.'s bid to unwind the U.S. Food and Drug Administration's refusal to classify a developing obesity treatment as a biological product appears to suffer from jurisdictional issues that might sink the company's appeal before its resolved, a Seventh Circuit judge signaled Thursday.

  • September 24, 2026

    ITC Takes On Patents, Trade Secrets In Large Decision Drop

    The U.S. International Trade Commission issued a flood of decisions this week on investigations in which imports are being evaluated to see if they infringe patents or misappropriate secrets, including three cases where it will reconsider holdings from administrative law judges.

Expert Analysis

  • How Cos. Can Avoid Infant Product False Advertising Suits

    Author Photo

    As lawsuits proliferate over products marketed for infant use and sold at a premium that are identical to cheaper general-use products, manufacturers should review related product lines, and scrutinize contextual cues that may contribute to the overall message received by consumers, say attorneys at Chamberlain Hrdlicka.

  • 9th Circ. Ruling Raises Bar For Arbitration Pacts Via Email

    Author Photo

    The Ninth Circuit's recent holding in Rickes v. Thermo Fisher that the mere delivery of an email doesn't establish an employee's assent to the arbitration agreement underscores that rollout processes should both give employees notice of the agreement and create evidence of their assent, say attorneys at Sullivan & Cromwell.

  • A Road Map To Modernizing Clinical Lab Regulations

    Author Photo

    The Centers for Medicare & Medicaid Services' recent request for comments on potential changes to the Clinical Laboratory Improvement Amendments provides an early indication of where CLIA is headed, and the operational, compliance, reimbursement and enforcement issues those changes will create, says Jose Vela at Clark Hill.

  • Where AI Patent Risk Begins And How Records Can Help

    Author Photo

    The Federal Circuit's recent decision in Dental Monitoring v. Align highlights the importance of documenting how artificial intelligence-assisted inventions work, and how humans contributed, as such records can support inventorship, written description, eligibility and definiteness requirements, say attorneys at Sterne Kessler.

  • 2nd Circ. Tylenol MDL Ruling Clarifies Court Gatekeeper Role

    Author Photo

    The Second Circuit’s recent decision in multidistrict litigation over alleged links between Tylenol and developmental disorders, holding that the trial court improperly excluded expert witnesses, preserves meaningful judicial gatekeeping while making clear that judges may not resolve legitimate scientific disputes themselves, say attorneys at Lowenstein Sandler.

  • Series

    Law School's Missed Lessons: Cultivating Good Judgment

    Author Photo

    Law schools generally overlook the role that solid judgment skills play in real-world practice, but attorneys can bridge the gap by strengthening their abilities to assess a case’s strengths and weaknesses, develop and execute effective strategies, and provide clear recommendations to clients, says Manny Caixeiro at Venable.

  • CMS Rule, DOJ Probes Deepen Gender Care Compliance Risk

    Author Photo

    The Centers for Medicare & Medicaid Services' final rule restricting Medicaid funding for hospitals that provide gender-affirming care is likely to face immediate litigation, but the CMS rulemaking is already working alongside U.S. Department of Justice's enforcement campaign to create operational risk for providers, say attorneys at Arnall Golden.

  • 2 Cases Shed Light On Invoking The 5th Before Congress

    Author Photo

    Given the anticipated increase in congressional investigations following the midterm elections, those who anticipate being in Congress' spotlight can draw valuable Fifth Amendment lessons from the ongoing case involving Dr. Anthony Fauci's testimony and the D.C. Circuit’s recent ruling in de la Torre v. Cassidy, say attorneys at King & Spalding.

  • Loper Bright Unlikely To Upend DEA Rescheduling Challenges

    Author Photo

    As cannabis industry stakeholders await a U.S. Drug Enforcement Administration ruling on broader cannabis rescheduling, the U.S. Supreme Court's 2024 decision in Loper Bright to eliminate judicial deference to agency decisions should not dramatically affect cannabis rescheduling litigation risk, but it could marginally strengthen proponents' hand if the DEA denies rescheduling, say attorneys at Dentons.

  • Vanda Ruling Offers New Guide To Generic Labeling Disputes

    Author Photo

    The D.C. Circuit's recent decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration is significant for its guidance on when generic-drug labeling remains sufficiently similar to brand labeling and when a difference requires a statutory exception, says Shashank Upadhye at Upadhye Tang.

  • Attorneys Using AI May Have Ethical Duty To Redact Docs

    Author Photo

    The trajectory of legal ethics guidance in recent years strongly suggests that as redaction technology becomes more accessible, the failure to use it when uploading highly confidential materials into artificial intelligence tools will become increasingly difficult to defend as reasonable, say attorneys at Lewis Brisbois.

  • Cannabis, Psychedelics Boom Raises IP Hurdles

    Author Photo

    Recent data regarding patent filing activity and litigation in the cannabis and psychedelics markets indicates that as commercial interest accelerates, the scope of publicly accessible prior art is also expanding, setting a higher bar for novelty and nonobviousness in patent applications, say attorneys at Sterne Kessler.

  • State AI Safety Laws Raise New Liabilities For Healthcare Cos.

    Author Photo

    Healthcare and life science companies using third-party artificial intelligence tools should pay particular attention to the changing state-level legal landscape, where the rollout of multiple AI safety laws is introducing both new compliance obligations and potential consumer protection liabilities, say attorneys at McDermott.

  • Series

    Juggling And Unicycling Make Me A Better Lawyer

    Author Photo

    Because I juggle (sometimes with fire) and ride the unicycle, friends and family used to joke that I should join the circus, but I pursued the practice of law instead and learned that my hobbies benefit my profession in several important ways, says Morgan Eddy at Smith Currie.

  • AI Note-Taking Suits May Fill Gap In Privacy Law Structure

    Author Photo

    A recent class action against Granola joins other pending lawsuits against AI note-taking providers, highlighting the legal uncertainty surrounding these tools, but there are practical steps companies using "invisible" AI services can take to mitigate risk, including conducting inventories and reviewing access permissions, say attorneys at Barnes & Thornburg.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.